|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Colorectal cancer with liver metastases:Neoadjuvant chemotherapy,surgical resection first or palliation alone?显示文摘Colorectal cancer(CRC) is one of the commonest cancers with 1.2 million new cases diagnosed each year in the world.It remains the fourth most common cause of cancer-related mortality in the world and accounts for > 600000 cancer-related deaths each year.There have been significant advances in treatment of metastatic CRC in last decade or so,due to availability of new active targeted agents and more aggressive approach towards the management of CRC,particularly with liver-only-metastases;however,these drugs work best when combined with conventional chemotherapy agents.Despite these advances,there is a lack of biomarkers to inform us about the accurate management of the patients with metastatic CRC.It is therefore imperative to carefully select the patients with comprehensive multi-disciplinary team input in order to optimise the management of these patients.In this review we will discuss various treatment options available in management of colorectal liver metastases with potential guidance on how and when to choose these options along with consideration on future directions in management of this disease. | Khurum Khan Anita Wale Gina Brown Ian Chau | 2014 | World Journal of Gastroenterology2014，20，35： | 22 |
| 2 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial显示文摘 | Tom Waddell Ian Chau David Cunningham David Gonzalez Alicia Frances Clare Okines Andrew Wotherspoon Claire Saffery Gary Middleton Jonathan Wadsley David Ferry Wasat Mansoor Tom Crosby Fareeda Coxon David Smith Justin Waters Timothy Iveson Stephen Falk Sar | 2013 | Lancet Oncology2013，，6： | 10 |
| 3 | Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial显示文摘 | Matthew T Seymour Sarah R Brown Gary Middleton Timothy Maughan Susan Richman Stephen Gwyther Catherine Lowe Jennifer F Seligmann Jonathan Wadsley Nick Maisey Ian Chau Mark Hill Lesley Dawson Stephen Falk Ann O’Callaghan Kim Benstead Philip Chambers Alfred | 2013 | Lancet Oncology2013，，8： | 6 |
| 4 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘 | Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell | 2014 | The Lancet2014，，9911： | 3 |
| 5 | Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study显示文摘 | Savtaj Brar Calvin Law Robin McLeod Lucy Helyer Carol Swallow Lawrence Paszat Rajini Seevaratnam Roberta Cardoso Matthew Dixon Alyson Mahar Laercio G. Lourenco Lavanya Yohanathan Alina Bocicariu Tanios Bekaii-Saab Ian Chau Neal Church Daniel Coit Christop | 2013 | Journal of the American College of Surgeons2013，，2： | 3 |
| 6 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘 | Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell | 2014 | 2014 (9911)2014，，9911： | 2 |
| 7 | Trastuzumab for gastric cancer treatment显示文摘 | Alicia FC Okines Alice Dewdney Ian Chau Sheela Rao David Cunningham | 2010 | The Lancet . 2010 (9754)2010，，9754： | 1 |
| 8 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘 | Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell | 2014 | The Lancet . 2014 (9911)2014，，9911： | 1 |
| 9 | Guidance on the management of diarrhoea during cancer chemotherapy显示文摘 | Jervoise Andreyev Paul Ross Clare Donnellan Elaine Lennan Pauline Leonard Caroline Waters Linda Wedlake John Bridgewater Rob Glynne-Jones William Allum Ian Chau Richard Wilson David Ferry | 2014 | Lancet Oncology2014，，10： | 1 |
| 10 | HER2 inhibition in gastro-oesophageal cancer:A review drawing on lessons learned from breast cancer显示文摘Human epidermal growth factor receptor 2(HER2)-inhibition is an important therapeutic strategy in HER2-amplified gastro-oesophageal cancer(GOC).A significant proportion of GOC patients display HER2 amplification,yet HER2 inhibition in these patients has not displayed the success seen in HER2 amplified breast cancer.Much of the current evidence surrounding HER2 has been obtained from studies in breast cancer,and we are only recently beginning to improve our understanding of HER2-amplified GOC.Whilst there are numerous licensed HER2 inhibitors in breast cancer,trastuzumab remains the only licensed HER2 inhibitor for HER2-amplified GOC.Clinical trials investigating lapatinib,trastuzumab emtansine,pertuzumab and MM-111 in GOC have demonstrated disappointing results and have not yet changed the treatment paradigm.Trastuzumab deruxtecan may hold promise and is currently being investigated in phase Ⅱ trials.HER2 amplified GOC differs from breast cancer due to inherent differences in the HER2 amino-truncation and mutation rate,loss of HER2 expression,alterations in HER2 signalling pathways and differences in insulin-like growth factor-1 receptor and MET expression.Epigenetic alterations involving different micro RNA profiles in GOC as compared to breast cancer and intrinsic differences in the immune environment are likely to play a role.The key to effective treatment of HER2 amplified GOC lies in understanding these mechanisms and tailoring HER2 inhibition for GOC patients in order to improve clinical outcomes. | Hazel Lote Nicola Valeri Ian Chau | 2018 | World Journal of Gastrointestinal Oncology2018，10，7： | 1 |
| 11 | Multiivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter,randomized,controlled trials using individual patient data显示文摘 | Ian Chau Andy R Norman David Cunningham | 2004 | J Clin Oncol2004，22，： | 1 |
| 12 | Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial显示文摘 | Matthew T Seymour Sarah R Brown Gary Middleton Timothy Maughan Susan Richman Stephen Gwyther Catherine Lowe Jennifer F Seligmann Jonathan Wadsley Nick Maisey Ian Chau Mark Hill Lesley Dawson Stephen Falk Ann O’Callaghan Kim Benstead Philip Chambers Alfred | 2013 | Lancet Oncology2013，，8： | 1 |
| 13 | Optimal Management of Gastric Cancer: Results From an International RAND/UCLA Expert Panel显示文摘 | Natalie Coburn Rajini Seevaratnam Lawrence Paszat Lucy Helyer Calvin Law Carol Swallow Roberta Cardosa Alyson Mahar Laercio Gomes Lourenco Matthew Dixon Tanios Bekaii-Saab Ian Chau Neal Church Daniel Coit Christopher H. Crane Craig Earle Paul Mansfield No | 2014 | Annals of Surgery2014，，1： | 1 |
| 14 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘 | Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell | 2014 | The Lancet2014，，9911： | 1 |
| 15 | Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial显示文摘 | Yu Jo Chua Yolanda Barbachano David Cunningham Jacqui R Oates Gina Brown Andrew Wotherspoon Diana Tait Alison Massey Niall C Tebbutt Ian Chau | 2010 | Lancet Oncology2010，，3： | 1 |
| 16 | Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies显示文摘 | Alice Dewdney David Cunningham Ian Chau | 2013 | The Oncologist2013，，7： | 1 |
| 17 | A randomized multicenter trial of epirubicin,oxaliplatin,and capecitabine(EOC)plus panitumumab in advanced esophagogastric cancer(REAL3)显示文摘 | Tom Samuel Waddell Ian Chau Yolanda Barbachano | 2012 | J Clin Oncol2012，30，： | 1 |
| 18 | Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer显示文摘AIM To investigate the impact of histology on outcome in advanced oesophageal cancer treated with first-line fluoropyrimidine-based chemotherapy.METHODS Individual patient data were pooled from three randomised phase Ⅲ trials of fluoropyrimidine-based chemotherapy ± platinum/anthracycline in patients with advanced, untreated gastroesophageal adenocarcinoma or squamous cell carcinoma(SCC) randomised between 1994 and 2005. The primary endpoint was overall survival of oesophageal cancer patients according to histology. Secondary endpoints were response rates and a toxicity composite endpoint.RESULTS Of the total 1836 randomised patients, 973 patients(53%)were eligible(707 patients with gastric cancer were excluded), 841(86%) had adenocarcinoma and 132(14%) had SCC. There was no significant difference in survival between patients with adenocarcinoma and SCC, with median overall survivals of 9.5 mo vs 7.6 mo(HR = 0.85, 95%CI: 0.70-1.03, P = 0.09) and one-year survivals of 38.8% vs 28.2% respectively. The overall response rate to chemotherapy was 44% for adenocarcinoma vs 33% for SCC(P = 0.01). There was no difference in the frequency of the toxicity composite endpoint between the two groups. CONCLUSION There was no significant difference in survival between adenocarcinoma and SCC in patients with advanced oesophageal cancer treated with fluoropyrimidine-based chemotherapy despite a trend for worse survival and less chemo-sensitivity in SCC. Tolerance to treatment was similar in both groups. This analysis highlights the unmet need for SCC-specific studies in advanced oesophageal cancer and will aid in the design of future trials of targeted agents. | Michael Davidson Ian Chau David Cunningham Komel Khabra Timothy Iveson Tamas Hickish Matthew Seymour Naureen Starling | 2017 | World Journal of Gastrointestinal Oncology2017，9，8： | 0 |
| 19 | Antibody drug conjugate development in gastrointestinal cancers:hopes and hurdles from clinical trials显示文摘Gastrointestinal(GI)cancers represent the leading cause of cancer-related mortality worldwide.Antibody drug conjugates(ADCs)are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival.ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy.Currently,only two ADCs[brentuximab vedotin and trastuzumab emtansine(T-DM1)]have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer,respectively.Clinical research evaluating ADCs in GI cancers has shown limited success.In this review,we will retrace the relevant clinical trials investigating ADCs in GI cancers,especially ADCs targeting human epidermal growth receptor 2,mesothelin,guanylyl cyclase C,carcinogenic antigen-related cell adhesion molecule 5(also known as CEACAM5)and other GI malignancy specific targets.We will review potential hurdles for their success and provide new perspective for future treatment. | Xiaorong Wu Thomas Kilpatrick Ian Chau | 2018 | Cancer Drug Resistance2018，1，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员